Higher number of tacrolimus dose adjustments in kidney transplant recipients who are extensive and intermediate CYP3A5 metabolizers

Kidney transplant recipients carrying the CYP3A5*1 allele have lower tacrolimus troughs, and higher dose requirements compared to those with the CYP3A5*3/*3 genotype. However, data on the effect of CYP3A5 alleles on post‐transplant tacrolimus management are lacking. The effect of CYP3A5 metabolism p...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical transplantation 2023-04, Vol.37 (4), p.e14893-n/a
Hauptverfasser:	Reininger, Kevin A., Onyeaghala, Guillaume, Anderson‐Haag, Teresa, Schladt, David S., Wu, Baolin, Guan, Weihua, Dorr, Casey R., Remmel, Rory P., Mannon, Roslyn, Matas, Arthur J., Oetting, William S., Stahler, Paul, Israni, Ajay K., Jacobson, Pamala A.
Format:	Artikel
Sprache:	eng
Schlagworte:	clinical management CYP3A5 Cytochrome P-450 CYP3A - genetics Cytochrome P-450 CYP3A - metabolism Genotype Humans Immunosuppressive Agents - therapeutic use Kidney Transplantation - methods kidney transplants Polymorphism, Single Nucleotide tacrolimus Tacrolimus - therapeutic use Transplant Recipients
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!